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Abstract
The histone deacetylase inhibitor FK228 has previously been shown to enhance adenoviral transgene expression when cells
are pre-incubated with the drug. Upregulation of the coxsackie adenovirus receptor (CAR), leading to increased viral
transduction, has been proposed as the main mechanism. In the present study, we found that the highest increase in
transgene expression was achieved when non-toxic concentrations of FK228 were added immediately after transduction,
demonstrating that the main effect by which FK228 enhances transgene expression is transduction-independent. FK228 had
positive effects both on Ad5 and Ad5/f35 vectors with a variety of transgenes and promoters, indicating that FK228 works
mainly by increasing transgene expression at the transcriptional level. In some cases, the effects were dramatic, as
demonstrated by an increase in CD40L expression by FK228 from 0.3% to 62% when the murine prostate cancer cell line
TRAMP-C2 was transduced with Ad[CD40L]. One unexpected finding was that FK228 decreased the transgene expression of
an adenoviral vector with the prostate cell-specific PPT promoter in the human prostate adenocarcinoma cell lines LNCaP
and PC-346C. This is probably a consequence of alteration of the adenocarcinoma cell lines towards a neuroendocrine
differentiation after FK228 treatment. The observations in this study indicate that FK228 enhances adenoviral therapy by a
transduction-independent mechanism. Furthermore, since histone deacetylase inhibitors may affect the differentiation of
cells, it is important to keep in mind that the activity and specificity of tissue- and tumor-specific promoters may also be
affected.
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Introduction
Viral vectors based on human adenovirus serotype 5 (Ad5) are
the most commonly used vectors for gene therapy and they are
frequently used for vaccination. In cancer gene therapy their effect
can be limited due to that malignant cells often have low
expression of the coxsackie adenovirus receptor (CAR), which is
the primary receptor for Ad5 [1]. Different means to increase
CAR expression on target cells would presumably lead to
enhanced adenoviral gene therapy efficacy.
Regulation of gene expression is controlled by various
mechanisms. Histone acetylation plays a key role in transcriptional
control by modulating chromatin structure [2]. In general, histone
acetylation is associated with relaxation of chromatin and
activation of transcription whereas histone deacetylation is
associated with condensation of the chromatin structure and
repression of transcription. Histone deacetylase inhibitors
(HDACi) cause accumulation of acetylated histones, which affect
transcription of specific genes and both up- and down-regulation
of gene expression can occur [3]. FK228, also known as
depsipeptide or romidepsin, is an HDACi that can induce cell
cycle arrest, promote apoptosis and inhibit angiogenesis [4].
FK228 triggers both mitochondrial-dependent [5] and mitochon-
drial-independent [6] apoptosis and is more toxic to malignant
than non-malignant cells [7]. Because of its direct cytotoxic effects,
FK228 has been and is currently being evaluated in clinical cancer
trials [8,9]. FK228 has minimal antitumor activity in patients with
metastatic castration-resistant prostate cancer [10]. In combina-
tion with docetaxel however, FK228 is able to enhance the
antitumor effect both in vitro and in prostate cancer xenograft
mouse models [11,12]. In addition, FK228 has been shown to
enhance the effect of adenoviral-mediated therapy [13,14]. The
mechanisms for this enhancement are not fully understood but
upregulation of CAR has been suggested as one possibility
[7,15,16,17,18].
Herein, we investigate the effect that FK228 has on adenoviral
transduction and transgene expression in cancer cells. Upregula-
tion of CAR plays if any, only a minimal role in the enhancement
of transgene expression. Instead, we show that FK228 has the
highest effect when administered directly after transduction,
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expression, probably by a general increment in transcription of the
host cell.
Materials and Methods
Cell lines
The prostate adenocarcinoma LNCaP, the colon carcinoma
HT-29 and the glioma U343 were cultured in RPMI-1640
supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES
and 1 mM sodium pyruvate. The prostate adenocarcinoma PC-
346C was cultured in DMEM:F-12 supplemented with 2% FBS,
0.01% bovine serum albumin, 10 mg/ml epidermal growth factor
(Sigma Aldrich, St. Louis, MO), 1% insulin-transferrin-selenium,
0.1 nM R1881 (NEN Life Science Products Inc, Boston, MA),
1.4 mM hydrocortisone (Sigma Aldrich), 0.6 ng/ml triiodothyro-
nine (Sigma Aldrich), 0.1 mM phosphoetanolamine, 50 ng/ml
cholera toxin (Sigma Aldrich), 0.1 mg/ml fibronectin (Sigma
Aldrich) and 20 mg/ml fetuin (Sigma Aldrich). The foreskin
fibroblast 1064SK and the human embryonic kidney 293FT were
cultured in DMEM supplemented with 10% FBS and 1 mM
sodium pyruvate. The endocrine pancreatic tumor cell line BON
was cultured in DMEM with Glutamax-I and F12 K Nutrient
Mixture (Kaighn’s Modification) at a 1:1 ratio, supplemented with
10% FBS and 1 mM sodium pyruvate. The murine prostate
adenocarcinoma TRAMP-C2 was cultured in DMEM supple-
mented with 5% FBS, 5% NuSerum (Becton Dickinson, Franklin
Lakes, NJ), 1 nM dihydrotestosterone (Sigma Aldrich) and 5 mg/
ml insulin (Sigma Aldrich). All medium contained 1% penicillin-
streptomycin. The cell culture reagents were from Invitrogen
(Carlsbad, CA) except when stated otherwise. All cell lines were
purchased from ATCC (Manassas, VA) except for BON that was a
kind gift from Dr. CM Townsend (Galveston, TX) and TRAMP-
C2 that was a kind gift from Dr. NM Greenberg (Baylor College of
Medicine, Houston, TX).
Isolation of peripheral blood mononuclear cells
Buffy coats from approximately 420 ml of blood were obtained
from five healthy volunteers. Peripheral blood mononuclear cells
(PBMC) were isolated by density centrifugation over Ficoll-Paque
(GE Healthcare, Bucks, UK). The PBMC fraction was obtained,
washed twice with PBS and resuspended in culture medium. The
cells were divided into five T-75 cell culture flasks and separated
by adhesion for 90 min. The non-adherent fraction (mainly
lymphocytes) was removed, and the adhesion fraction (mainly
monocytes) was washed twice with PBS, trypsinized, counted and
used for transduction.
Viral vectors
The recombinant serotype 5-based adenoviral vectors used in
this study have been described previously: Ad[Mock] [19], Ad5 wt
[20], Ad[i/PPT-LUC] [20], Ad[CMV-LUC] [21], Ad[i/PPT-
E1A, E3] [20], Ad[CMV-GFP] [21], Ad[CD40L] [22], and
Ad[CgA-LUC] [23]. One new vector, Ad[I/PPT-GFP] was made
by replacing the luciferase transgene in Ad[I/PPT-LUC] [21] with
the sequence encoding enhanced green fluorescent protein (GFP)
by using HindIII and XbaI. A serotype 5 adenoviral vector with
the fiber shaft and knob from serotype 35, Ad5/f35[CMV-GFP],
was a kind gift from Dr Fan (Lund University, Lund, Sweden) and
has been described and evaluated before [24,25]. The vectors were
produced, purified and titrated as described earlier [20].
A vesicular stomatitis virus (VSV)-G protein pseudotyped self-
inactivating (SIN) lentiviral vector with a CMV-GFP expression
cassette was produced, LN[CMV-GFP]. For lentiviral vector
production, 293FT cells were grown in 15 cm plates to a
confluence of 80–90% and transfected with 8.1 mg pRRL-CMV-
GFP (kind gift from Dr. F Carlotti, Leiden University Medical
Center, Leiden, The Netherlands), 4.05 mg pLP1 (gag/pol),
4.05 mg pLP2 (rev), and 4.05 mg pLP/VSVG using 60 ml
Lipofectamine 2000 per plate. Viral supernatants were collected
after 48 h, filtered (0.45 mm) and concentrated by ultracentrifu-
gation at 75,000 g for 90 min at 4uC using a Sorvall AH629 rotor.
The viral pellet was resuspended in PBS and stored at 280uC until
further use. Viral titer was determined by the HIV-1 p24 Antigen
ELISA from ZeptoMetrix Corporation (Buffalo, NY) according to
instructions from the manufacturer.
Cell viability assay
Prostate cancer cells were treated with various concentrations of
FK228 (Fujisawa Pharmaceuticals Co., Ltd., Osaka, Japan)
ranging from 0.1 ng/ml to 300 ng/ml and then plated in 96 well
plates (7500 cells/well). After 24, 48 and 72 h, cell viability was
determined by the MTS Cell Titer 96 Aqueous One Solution
Proliferation Assay Kit (Promega, Madison, WI) according to the
manufacturer’s instructions. Average enzymatic activity from
triplicate samples was expressed in relation to average activity in
untreated cells.
Green fluorescent protein reporter gene analysis
Cells were transduced in suspension for 2 h with Ad[CMV-
GFP], Ad5/f35[CMV-GFP] and Ad[I/PPT-GFP] at various
MOIs ranging between 0.1 and 300 FFU/cell depending on the
cell line. Cells were also transduced with LN[CMV-GFP] using
0.3 vp/cell for all cell lines. Cells were either pre-treated with
FK228 (3 ng/ml) for 24 h before transduction and/or incubated
with FK228 2 h after transduction. Transduced monocytes were
incubated with 1 ng/ml depsi. The HDACi valproic acid (VPA)
from Sigma Aldrich was always added 2 h after transduction at a
concentration of 5 mM. Cells were harvested 48 h after
transduction and analyzed with FACSCalibur Flow Cytometer
(San Diego, CA).
Analysis of cell surface receptors
Cells were incubated with standard medium or medium
containing FK228 (3 ng/ml) for 48 h at 37uC. Cells were then
harvested and stained with antibodies (30 min, 4uC) for the
following surface receptors using mouse monoclonal antibodies:
CAR (RmcB hybridoma, ATCC, Manassas, VA), CD46 (BD
Biosciences), aVb3 (Chemicon, Temecula, CA) and aVb5
(Chemicon). After washing, the cells were incubated with a
FITC-labeled rabbit-anti-mouse antibody (Dako, Glostrup, Den-
mark) for 30 min at 4uC followed by washing. A mouse isotype-
matched antibody (Dako) and the FITC-labeled secondary
antibody were used as controls. The samples were analyzed by
FACSCalibur Flow Cytometer. Mean fluorescence intensity (MFI)
of receptor expression of FK228 treated cells was related to
untreated cells.
Analysis of CD40L expression
Cells were transduced with Ad[CD40L] for 2 h, washed and
then incubated with medium containing various concentrations of
FK228. Cells were stained 24 h thereafter with a PE-conjugated
antibody against CD40L (Pharmingen, San Diego, CA). An
isotype-matched PE-conjugated antibody (Pharmingen) was used
as negative control. Cells were stained with antibodies for 15 min
at room temperature. Expression of surface CD40L was analyzed
by flow cytometry (FACSCalibur).
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The luciferase reporter gene assay has been described earlier
[20]. Briefly, LNCaP cells were transduced with Ad[i/PPT-LUC],
Ad[CgA-LUC] and Ad[CMV-LUC] at an MOI of 50 FFU/cell
and BON cells were transduced with Ad[CgA-LUC] and
Ad[CMV-LUC] at an MOI of 10 FFU/cell in suspension for
2 h. Thereafter, fresh medium alone or fresh medium with FK228
(3 ng/ml) or VPA (5 mM) was added. After 48 h of incubation at
37uC cells were lysed and luciferase activity was measured using a
Wallac VICTOR
2 multilabel counter (PerkinElmer, Turku,
Finland). Background levels were subtracted and luciferase
activities were related to total protein concentrations in the
samples (relative luciferase units per mg protein, RLU/mg).
Replication assay
LNCaP and PC-346C cells were transduced with Ad5[i/PPT-
E1A, E3] and Ad5 wt in suspension at an MOI of 10 and 1 FFU/
cell respectively. BON was transduced with Ad[CgA-E1A] and
Ad5 wt at an MOI of 1 FFU/cell. After 2 h the cells were washed
and resuspended in medium with or without FK228 (3 ng/ml) or
VPA (5 mM). After 72 h of incubation at 37uC, cells and medium
were collected and viral DNA was purified using High Pure Viral
Nucleic Acid Kit (Roche, Mannheim, Germany), according to the
manufacturer’s instructions. Viral DNA content was analyzed by
quantitative real time PCR (qPCR) using the iCycler IQ real-time
detection system (Bio-Rad, Hercules, CA). The specific PCR
product was continuously measured during 40 cycles (95uC for
15 sec, 60uC for 60 sec) using iQ SYBR Green supermix (Bio-
Rad) and primers in the adenovirus E4 region: 5’-CAT CAG
GTT GAT TCA CAT CGG-3’ (E4.Forward) and 5’-GAA GCG
CTG TAT GTT GTT CTG-3’ (E4.Reverse). All samples were
amplified in triplicates. Copy numbers were related to a standard
curve made by serial dilutions of a plasmid containing E4 open
reading frame 1 (pCR2.1(Ad5E4orf1)). Relative replication was
defined as the increase in copy number compared to input virus
(also measured by qPCR).
Gene expression
LNCaP and PC-346C cells were transduced with Ad[i/PPT-
LUC] at MOI 10 FFU/cell and then treated with 3 ng/ml FK228
or 5 mM VPA for 48 h. Cells were then collected and RNA was
extracted using RNeasy Mini Kit (Qiagen, Hilden, Germany).
Three mg of total RNA and 1 ml SuperScript II Reverse
Transcriptase (Invitrogen) were used for cDNA synthesis. The
expression of prostate epithelial cell-associated genes [androgen
receptor (AR), androgen receptor coregulator (ARA24), prostate-
specific antigen (PSA), prostate-specific membrane antigen
(PSMA), 5-a reductase type 1 and 2 (SRD5A1 and SRD5A2)
and T cell receptor c-chain alternate reading frame protein
(TARP)] and neuroendocrine-associated genes [b-tubulin III (b-
tubIII), chromogranin A (CgA), neuron-specific enolase (NSE) and
synaptophysin (SYP)] was analyzed by quantitative PCR with the
same protocol as for the replication assay, described above. The
primer sequences are listed in Table S1. RNA levels in FK228 and
VPA treated cells were related to RNA levels in untreated cells.
Statistical analysis
Statistical analysis was done using the GraphPad Prism version
4.03 (GraphPad Software, San Diego, CA). One-way analysis of
variance followed by Dunnet’s post test was used to compare
luciferase activities and replication. The p value is less than 0.05
for the luciferase assay and less than 0.0001 for the replication
assay.
Results
FK228 above 3 ng/ml reduces viability of prostate cancer
cell lines
Cell viability studies were performed to determine FK228
toxicity for the human prostate cancer cell lines LNCaP and PC-
346C and the mouse prostate cancer cell line TRAMP-C2. Cells
were cultured in medium containing FK228 for 24, 48 and
72 hours before MTS assay analysis. After 72 h of incubation at
3 ng/ml FK228, around 80% of LNCaP and PC-346C cells were
viable. TRAMP-C2 appeared to be somewhat less sensitive to
FK228 than LNCaP and PC-346C. Reduced cell viability was
observed at FK228 concentrations of 3 ng/ml and above for all
cell lines and time points (Figure 1).
Addition of FK228 after transduction enhances transgene
expression of Ad[CMV-GFP] more than addition of FK228
before transduction
We next wanted to investigate the effect of FK228 on adenoviral
transduction. LNCaP, PC-346C and TRAMP-C2 were grown in
medium with or without 3 ng/ml FK228 for 24 h. Subsequently,
cells were transduced with Ad[CMV-GFP] for 2 h and then
cultured in medium with or without FK228 for another 48 h. GFP
expression was analyzed by flow cytometry. Pre-incubation of cells
with FK228 enhanced GFP expression to some extent in LNCaP
and TRAMP-C2 (Figure 2). Pre- and post-incubation gave an
even higher level of GFP expression in all three cell lines.
However, the highest increase was observed when FK228 was
added after transduction, indicating a post-transductional effect of
FK228. The fact that FK228 had the largest effect when given
after transduction, both when looking at percentage of GFP
positive cells and mean fluorescence intensity (MFI), indicates that
the receptors involved in adenoviral transduction may play a less
important role for enhanced transgene expression as previously
proposed. Next, we used both the serotype 5-based vector
Ad[CMV-GFP] and the adenoviral serotype 5 vector with fiber
shaft and knob from serotype 35 Ad5/f35[CMV-GFP] to screen
cell lines of various origin as well as freshly isolated human
monocytes. Treatment of cells with FK228 after transduction
enhanced GFP expression (both percentage and MFI) in all cell
lines and monocytes for both viruses (Figure 3). The effect was not
as pronounced for a lentiviral vector with regard to GFP positive
cells as FK228 increased GFP expression of LN[CMV-GFP] in
TRAMP-C2 cells but had no effect in the other cell lines tested
(Figure S1). The MFI values on the other hand were increased in
all cells except for BON and monocytes.
FK228 does not upregulate cell surface receptors needed
for adenoviral infection
To investigate if FK228 upregulate cell surface receptors needed
for adenoviral infection (CAR and aVb3 and aVb5 integrins for
Ad5 and CD46 for Ad5/f35), cells were treated with FK228 for
48 h and then stained for receptor expression and evaluated by
flow cytometry. The receptor expression of FK228-treated cells
was related to the expression in untreated cells (set to 1.00). Most
cell lines did not show any marked difference in surface receptor
expression after treatment of FK228 (values at 1.00625%, Table
S2). In the 1064SK fibroblasts the mean fluorescence intensity
doubled for CAR and increased by 50% for aVb3 after treatment
with FK228. Some increase of CAR was observed also in U343
and the mean fluorescence value for aVb5 in LNCaP and CD46
in PC-346C was reduced by approximately 50% upon treatment
with FK228. Overall, the changes in receptor expression was if
FK228 Enhances Ad5 Expression
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that receptor upregulation is not the main reason for increased
transgene expression after adenoviral transduction.
FK228 treatment enhances adenoviral-mediated CD40L
expression in prostate cancer cells
Since FK228 had an effect on the GFP transgene we next
wanted to investigate if it can increase also therapeutic transgene
expression. An Ad5-based vector with the therapeutic CD40
ligand transgene driven by the CMV promoter, Ad[CD40L], was
studied in prostate cancer cell lines. Cells were transduced with the
vector for 2 h, washed and then incubated with or without various
concentrations of FK228. After 24 h of incubation, the cells were
stained for CD40L expression and analyzed by flow cytometry.
FK228 treatment increased the percentage of CD40L-expressing
cells as well as MFI in a dose-dependent manner (Figure 4). The
most pronounced effect was observed in TRAMP-C2 cells, which
are normally difficult to transduce with Ad5-based vectors. At an
MOI as low as 3 FFU/cell, the percentage of CD40L-expressing
cells increased from 0.3% for untreated cells to 62% for FK228-
treated (3 ng/ml) cells. At MOI 0.3, FK228 treatment increased
CD40L expression about 3 times in LNCaP and 2 times in PC-
346C.
HDAC inhibitors affect transgene expression driven by
the prostate-specific PPT promoter negatively in prostate
cancer cell lines
After finding out that FK228 increases transgene expression
from various viral vectors, we wanted to investigate if FK228 had
the same positive effect on adenoviral vectors with tissue-specific
promoters as it has on an adenoviral vectors with the CMV
promoter. The human chromogranin A (CgA) promoter was
positively affected, although not significantly, by FK228 and VPA
when the neuroendocrine pancreatic carcinoid cell line BON was
transduced with Ad[CgA-LUC] (Figure 5A). A vector with the
same transgene driven by the CMV promoter was used for
comparison. Next, LNCaP and PC-346C cells were transduced
with Ad[i/PPT-LUC and Ad[i/PPT-GFP] and thereafter incu-
bated with FK228 or VPA for 48 h. Interestingly, the PPT-driven
transgene expression of both luciferase (Figure 5A) and GFP
(Figure 5B) was decreased when the cells were incubated with
either of the two HDACi while, as before, CMV-driven GFP
expression was increased when cells were treated with FK228 after
transduction. VPA treatment increased the expression of both
luciferase and GFP when the CMV promoter was used (Figure 5A
and 5B). Of further interest, when the prostate cancer cell lines
LNCaP and PC346-C were transduced with the neuroendocrine-
selective Ad[CgA-LUC] vector and then treated with FK228 or
VPA, we found that transgene expression was increased.
Figure 2. Addition of FK228 after adenoviral transduction
enhances transgene expression. Prostate cancer cell lines were
grown in medium with or without 3 ng/ml FK228 for 24 h (before). Cells
were then transduced with Ad[CMV-GFP] for 2 h, washed and then
cultured in medium with or without FK228 for another 48 h (after). The
percentages of GFP positive cells (upper right) and MFI values (lower
right) are given. The highest transgene expression was observed when
FK228 was administered after transduction. One representative set out
of three experiments is shown.
doi:10.1371/journal.pone.0014700.g002
Figure 1. FK228 concentrations above 3 ng/ml reduce cell
viability in prostate cancer cells. TRAMP-C2, LNCaP and PC-346C
cells were treated with various concentrations of FK228 (ranging from
0.1 ng/ml to 300 ng/ml) for 24, 48 and 72 h. Cell viability measured by
the MTS assay is expressed in relation to the activity in untreated cells.
FK228 concentrations higher than 3 ng/ml reduced viability in all cell
lines.
doi:10.1371/journal.pone.0014700.g001
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negatively affected by FK228 and VPA, we also wanted to study if
replicationofaPPT-controlledoncolyticadenoviruswasdecreasedas
well. LNCaP and PC-346C cells were transduced with the
conditionally replicating Ad[i/PPT-E1A, E3] and Ad5 wt and
BON cells were transduced with Ad[CgA-E1A] and Ad5 wt. The
cells were then incubated in medium containing either FK228 or
VPA for 72 h. Viral copy numbers were determined by quantitative
PCR. Replication of the PPT-driven virus was decreased by FK228
in LNCaP (1.6 times) and PC-346C (1.3 times). VPA treatment
reduced replication to a higher extent; 7.7 times in LNCaP and 126
times in PC-346C (Figure 6). In BON cells, a decrease (1.7 times) in
replication was observed in Ad[CgA-E1A]-transduced cells treated
with VPA (Figure 6). Replication of Ad5 wt was not affected in BON
cells but reduced in LNCaP and PC-346C.
HDACi differentiate virus-transduced prostate cancer
cells along the neuroendocrine lineage
The increased transgene expression from Ad[CgA-LUC] in the
prostate cancer cell lines LNCaP and PC346-C and the decreased
expression of Ad[i/PPT-LUC] upon HDACi treatment led us to
further investigate the effect of FK228 or VPA on these cell lines.
RNA expression of the genes normally controlled by the
regulatory elements of PPT: PSA, PSMA and TARP were
therefore evaluated along with genes involved in the androgen
receptor pathway: AR, ARA24, SRD5A1 and SRD5A2, since the
PPT promoter is partly regulated by testosterone. The prostate
epithelial cell-associated genes: AR, ARA24, PSA, PSMA,
Figure 4. FK228 treatment enhances adenoviral-mediated
CD40L expression. Prostate cancer cell lines were transduced with
various MOI of Ad[CD40L] and cultured in medium with various
concentrations of FK228 for 24 h. Cell surface expression of CD40L was
analyzed by flow cytometry. Percentages of CD40L positive cells (upper
right) and MFI values (lower right) are given. FK228 increased CD40L
expression in a dose-dependent manner. One representative experi-
ment out of three is shown.
doi:10.1371/journal.pone.0014700.g004
Figure 3. FK228 enhances transgene expression in various cell
types. Cells were transduced with Ad[CMV-GFP] or Ad5/f35[CMV-GFP]
for 2 h and then incubated for 48 h in medium containing 3 ng/ml
FK228. The percentages of GFP positive cells (upper right) are given as
well as MFI values (lower right or left). FK228 enhanced transgene
expression of Ad5 virus and Ad5 virus with fiber shaft and knob from
serotype 35 in all cell lines. Each cell line was evaluated three times with
similar results. Monocytes from five different donors were evaluated.
Representative examples are displayed in the figure.
doi:10.1371/journal.pone.0014700.g003
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than 2-fold up- or down-regulation) by the FK228 and VPA
treatment. However, in LNCaP, the expression of AR was slightly
decreased to just below a 2-fold down-regulation for both HDACi.
In PC-346C, the expression of SRD5A1 was increased after VPA
treatment and SRD5A2 expression was increased after both
FK228 and VPA treatment while PSMA expression (VPA
treatment) and TARP expression (FK228 and VPA treatment)
were decreased (Figure 7).
We observed that the activity of the CgA promoter increased by
treatment of FK228 and VPA in LNCaP and PC-346C.
Furthermore, VPA is known to induce neuroendocrine differen-
tiation in LNCaP by upregulation of b-tubIII, NSE and SYP
[26,27]. RNA levels of these elements were therefore also assessed.
Therefore, expressions of the neuroendocrine-associated genes: b-
tubIII, CgA, NSE and SYP were evaluated. We found them all to
be greatly increased in HDACi-treated LNCaP and PC-346C
cells (Figure 7), indicating that HDACi promotes differentiation
along the neuroendocrine lineage for these adenocarcinoma cell
lines.
Discussion
HDACi have been shown to increase the effect of adenoviral-
mediated gene therapy although the mechanisms are not fully
understood [13,14,28]. Upregulation of CAR, the primary
receptor for Ad5 infection, has been suggested as a possible
mechanism [7,15,16,17,18]. However, in those studies the amount
of CAR was determined by measurement of RNA levels by
quantitative real-time PCR or protein levels by western blot
analysis. Determination of RNA and total protein levels does not
determine receptor functionality and the results can therefore be
misleading. We measured instead the quantity of CAR and
integrins, which are also needed for Ad5 infection on the surface of
cells by flow cytometry, since it is the most appropriate technique
to address receptor expression. We found that neither CAR nor
integrins were upregulated after 48 h of treatment with non-toxic
concentrations of FK228. Furthermore, when prostate cancer cells
were transduced with Ad[CMV-GFP], the amount of GFP-
expressing cells was much higher when FK228 treatment was
given after transduction compared to when cells had been pre-
Figure 5. HDAC inhibitors affect tissue-specific promoters differently. A) BON cells were transduced with Ad[CgA-LUC] and Ad[CMV-LUC]
and LNCaP and PC-346C were transduced with Ad[i/PPT-LUC], Ad[CgA-LUC] and Ad[CMV-LUC]. Cells were then incubated with 3 ng/ml FK228 or
5 mM VPA for 48 h. Both FK228 and VPA enhanced the transgene expression of the Ad[CgA-LUC] vector in BON cells about 10 times although the
increase was not significant. In LNCaP and PC-346C, the expression of Ad[i/PPT-LUC] was significantly decreased while the expression of Ad[CgA-LUC]
was significantly increased by HDACi treatment. B) LNCaP and PC-346C cells were transduced with Ad[I/PPT-GFP] and Ad[CMV-GFP] and then
incubated with 3 ng/ml FK228 or 5 mM VPA for 48 h followed by flow cytometry analysis. The percentages of GFP positive cells (upper right) and MFI
values (lower right) are given. GFP levels were decreased by HDAC inhibitors when the transgene expression was controlled by the PPT promoter.
One representative experiment out of three is shown. Significance (p,0.05) is indicated with asterisks.
doi:10.1371/journal.pone.0014700.g005
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that transgene expression is enhanced by a transduction-
independent mechanism.
Association of cellular histones with the viral genome DNA in
infected cells remains controversial [29,30,31,32]. However, by
using chromatin immunoprecipitation (ChIP) assays, Komatsu et al
recently showed that viral chromatin is associated with both viral
protein VII and cellular histones with post-translational modification
(acetylation of histone H3) in infected cells [33]. They also showed
that acetylation of histone H3 occurs at the promoter regions of
active viral genes. Among a variety of histone modifications,
acetylation at K9 and/or K14 of histone H3 is in fact recognized
as an active chromatin mark for transcription [34]. It is therefore
possible that FK228 affects histones associated with viral DNA and
therefore enhances adenoviral transgene expression at the transcrip-
tional level. However, this remains to be investigated.
Since we observed that FK228 administered directly after
adenoviral transduction had a visible effect on transgene
expression, we went on to investigate the effect of FK228 in a
number of experimental models where it could be therapeutically
beneficial. Monocytes are precursors of dendritic cells and as such,
highly interesting as cancer vaccines after being modified to
Figure 6. Virus replication is decreased by treatment of HDAC inhibitors. LNCaP and PC-346C were transduced with Ad[i/PPT-E1A, E3] and
Ad5 wt and BON cells were transduced with Ad[CgA-E1A] and Ad5 wt. The cells were then incubated in medium with 3 ng/ml FK228 or 5 mM VPA for
72 h. Viral copy numbers were determined by quantitative PCR and related to the values obtained 2 h after transduction. Replication was decreased
by FK228 and VPA treatment in most cases. Significance (p,0.0001) is indicated with asterisks.
doi:10.1371/journal.pone.0014700.g006
Figure 7. Differential gene expression in virus-transduced prostate cancer cells after 48 h of treatment with HDAC inhibitors. LNCaP
and PC-346C were transduced with Ad[i/PPT-LUC] and then incubated with 3 ng/ml FK228 or 5 mM VPA for 48 h. RNA was extracted, cDNA was
produced and gene expression was evaluated by quantitative PCR (triplicate samples). Gene expression in FK228 and VPA-treated cells was related to
untreated cells. A two-fold difference in gene expression was set as a limit for true difference. The expression of prostate-associated genes (AR,
ARA24, PSA, PSMA, SRD5A1, SRD5A2 and TARP) was not considerably affected by the HDACi. The expression of neuroendocrine-associated genes (b-
tubIII, CgA, NSE and SYP) was increased in HDACi-treated cells.
doi:10.1371/journal.pone.0014700.g007
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adenoviral vector carrying the transgene coding for the tumor-
associated antigen. For example, efficient adenoviral transduction
of monocytes is highly warranted for ex vivo generation of T cells
against specific antigens [35]. Such T cells could then be used for
adoptive transfer to cancer patients. First, we observed that by
using Ad5/f35 instead of Ad5 the amount of viral vector needed
for transduction of monocytes could be lowered four times
compared to Ad5 vectors (from 20 FFU/cell for Ad5 to 5 FFU/
cell for Ad5/f35). We then asked ourselves if FK228 could
improve transgene expression even further and we found that
addition of FK228 after transduction doubled transgene expres-
sion both for Ad5 and Ad5/f35. These data imply that HDACi
may increase the effect of adenoviral-based vaccination strategies,
importantly also for Ad5/f35-based vectors.
The strategy to use adenoviral-mediated CD40L gene therapy
to induce anti-tumor immunity has been employed in several
cancer models [36] and it has recently been evaluated in a phase
I/IIa clinical trial for bladder carcinoma [37]. In a previous study,
we demonstrated that administration of Ad[CD40L] can suppress
tumor growth and prolong survival of mice with subcutaneous,
syngenic TRAMP-C2 tumors [38]. However, relatively high
amount of the vector is needed to suppress tumor growth since
mouse cells are semi-permissive for infection of human adenoviral
vectors. We observed that addition of non-toxic concentrations of
FK228 after transduction with Ad[CD40L] enhanced CD40L
expression in a dose-dependent manner in prostate cancer cell
lines in vitro. For TRAMP-C2 cells, which normally are hard to
transduce with Ad5 [38], CD40L-expressing cells increased
dramatically from 0.3% without treatment to 62% with FK228
treatment after viral transduction at MOI 3. This suggests that
FK228 can be combined with Ad[CD40L] treatment and possibly
with any other adenoviral vector when increased expression of a
therapeutic gene is desired, i.e., lower amounts of adenoviral
vectors would be required to achieve a therapeutic response.
The use of tissue-specific promoters is an attractive approach to
restrict transgene expression of adenoviral vectors and replication
of oncolytic adenoviruses to certain organs [39,40]. We have
previously reported on adenoviral vectors with the prostate cell-
specific PPT promoter that consists of the PSA enhancer, the
PSMA enhancer and the TARP promoter [21]. We have also
shown that oncolytic Ad5 viruses with the PPT promoter
selectively reduce cell viability of prostate cancer cell lines
[20,41] and we therefore wanted to study the putatively additive
effect of adding HDAC inhibitors. However, we found that
although an adenoviral vector with the CMV promoter yields
higher transgene expression (GFP and luciferase) after treatment of
LNCaP and PC-346C with the HDACi FK228 and VPA, the
opposite was observed for the recombinant PPT promoter. One
possible explanation for this is that the PPT promoter is directly
affected by HDACi but a more plausible explanation is that
HDACi affect gene expression and cell differentiation of LNCaP
and PC-346C. Gene expression profiling experiments have
revealed that HDACi including FK228 induce changes in genes
coding for transcription/translation factors and factors involved in
metabolism, differentiation and cell cycle [42,43,44]. Furthermore,
VPA and other HDACi have been shown to promote neuroen-
docrine-like differentiation of LNCaP cells [26,27]. We speculate
that also FK228 induce neuroendocrine differentiation of LNCaP
and that the activity of the PPT promoter therefore is decreased
since its activity is restricted to normal and neoplastic prostate
epithelial cells. In fact, four neuroendocrine-associated genes, b-
tubIII, CgA, NSE and SYP, were upregulated in LNCaP and PC-
346C after treatment with either FK228 or VPA. Furthermore, we
also observed that CgA promoter-controlled transgene expression
increased in LNCaP and PC-346C upon HDACi treatment after
adenoviral vector transduction, again indicating cell differentiation
along the neuroendocrine lineage.
VPA has previously been shown to hamper the adenovirus
major late promoter thus affecting replication in a negative
manner [45]. The PPT promoter did not lose its activity
completely and we found that the replication of Ad[i/PPT-E1A,
E3] in LNCaP and PC-346C was decreased by FK228, although
the decrease was small, while VPA decreased the replication to a
higher extent. The reason for this observation might be that there
is still enough E1A produced by the PPT promoter to ensure
efficient replication after FK228 treatment but not after VPA
treatment. However, since the reporter gene expression driven by
PPT was decreased and the replication was not improved it
appears that it is not meaningful to use FK228 or VPA together
with an oncolytic adenovirus controlled by this particular
promoter. The transgene expression driven by another tissue-
specific promoter, the neuroendocrine cell-specific chromogranin
A (CgA) promoter [23] was evaluated in the endocrine pancreatic
cell line BON. We found that the activity of this promoter behaved
as the CMV promoter; the expression of the luciferase transgene
increased after treatment of transduced cells with both FK228 and
VPA. The replication of Ad[CgA-E1A] was not affected by FK228
but was reduced by VPA. We predict that most promoters will
yield higher transgene expression in target tissues when FK228 or
VPA are used in conjunction with adenoviral transduction.
However, it is unlikely that HDACi will increase replication of
viral vectors as neither of the two HDACi increased the replication
of wild type Ad5 nor the tissue-restricted viruses investigated in the
present study.
We conclude from the results in this study that the HDACi
FK228 can be used to enhance CMV-driven and CgA-driven
transgene expression of Ad5 and Ad5/35 viruses in cell lines and
human monocytes. The mechanism for this enhancement seems to
be transduction-independent since the highest transgene expres-
sion was observed when FK228 was administered after transduc-
tion. We therefore discourage from using FK228 as pre-treatment
to adenoviral transduction and suggest evaluation of simultaneous
administration of vector and FK228 or that FK228 is administered
after vector treatment in pre-clinical animal models. HDACi may
influence differentiation of cells and can therefore change the
activity and selectivity of tissue-specific promoters, as was observed
with the prostate cell-specific PPT promoter. For that reason, we
propose careful investigation of HDACi effects on target cells and
their interaction with viral vectors before usage. Since neither
FK228 nor VPA resulted in increased replication of Ad5 wt and
the tissue-restricted viruses, the use of HDACi is not likely to be
beneficial for oncolytic therapy.
Supporting Information
Figure S1 FK228 does not improve transgene expression of a
lentiviral vector. Cell lines were transduced with LN[CMV-GFP]
at 0.3 vp/cell and monocytes at 3 vp/cell followed by incubation
for 48 h in medium containing 3 ng/ml FK228. The percentages
of GFP positive cells (upper right) and MFI values (lower right) are
given. For most cell types as well as monocytes, FK228 did not
enhance GFP expression. In TRAMP-C2 however, the GFP
expression was doubled in FK228-treated cells.
Found at: doi:10.1371/journal.pone.0014700.s001 (1.10 MB TIF)
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